Traumatic Brain Injury - Pipeline Review, H2 2015 Summary Global Markets Direct s, Traumatic Brain Injury - Pipeline Review, H2 2015, provides an overview of the Traumatic Brain Injurys therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Traumatic Brain Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Traumatic Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Traumatic Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Browse Complete Report with TOC @http://www.idatainsights.com/reports-landing-page.php?id=124190/traumatic-brain-injury-pipeline-review-h2-2015
To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=124190/traumatic-brain-injury-pipeline-review-h2-2015
Table of Contents
Table of Contents
2 List of Tables
6 List of Figures
8 Global Markets Direct Report Coverage
8 Traumatic Brain Injury Overview
9 Therapeutics Development
10 Pipeline Products for Traumatic Brain Injury - Overview
10 Pipeline Products for Traumatic Brain Injury - Comparative Analysis
11 Traumatic Brain Injury - Therapeutics under Development by Companies
12 Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes
17 Traumatic Brain Injury - Pipeline Products Glance 18 Late Stage Products
18 Clinical Stage Products
19 Early Stage Products
20 Unknown Stage Products
21 Traumatic Brain Injury - Products under Development by Companies
22 Traumatic Brain Injury - Products under Investigation by Universities/Institutes
27 Traumatic Brain Injury - Companies Involved in Therapeutics Development
28 Adamas Pharmaceuticals, Inc.
28 ALSP, Inc.
29 Amarantus Bioscience Holdings, Inc.
30 Athersys, Inc.
31 BHR Pharma, LLC
32 Cognosci, Inc.
33 Euroscreen S.A.
34 Grupo Ferrer Internacional, S.A.
35 International Stem Cell Corporation 36 Io Therapeutics, Inc.
38 Karyopharm Therapeutics, Inc.
39 Kyorin Pharmaceutical Co., Ltd.
40 Levolta Pharmaceuticals, Inc.
41 Lixte Biotechnology Holdings, Inc.
42 Lpath, Inc. 43 MandalMed, Inc.
44 Mapreg S.A.S.
45 Mnemosyne Pharmaceuticals, Inc.
46 Neuralstem, Inc.
47 Neuren Pharmaceuticals Limited 48 NeuroHealing Pharmaceuticals Inc.
49 NeuroNascent, Inc.
50 Neuronax SAS
51 NeuroVive Pharmaceutical AB
52 Omeros Corporation
53 PharmatrophiX, Inc.
54 Phylogica Limited
55 Prevacus, Inc.
56 PsychoGenics, Inc.
57 QR Pharma, Inc.
58 RAPID Pharmaceuticals AG
59 RegeneRx Biopharmaceuticals, Inc.
60 Remedy Pharmaceuticals, Inc.
61 Sage Therapeutics 62 SanBio, Inc.
63 STATegics, Inc.
64 Tetra Discovery Partners LLC
65 VG Life Sciences, Inc.
66 Traumatic Brain Injury - Therapeutics Assessment
67 Assessment by Monotherapy Products
67 Assessment by Combination Products
68 Assessment by Target 69 Assessment by Mechanism of Action
72 Assessment by Route of Administration
75 Assessment by Molecule Type
77 Drug Profiles 79 2-DG - Drug Profile
79 ALP-496 - Drug Profile 81 amantadine hydrochloride ER - Drug Profile
83 AMRS-001 - Drug Profile
85 apomorphine hydrochloride - Drug Profile
88 AST-002 - Drug Profile
90 AVL-8168 - Drug Profile
91 Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile
92 CHEC-7 - Drug Profile 94 CHEC-9 - Drug Profile
95 CMX-2043 - Drug Profile 97 CNB-001 - Drug Profile
99 COG-1410 - Drug Profile
101 cyclosporine - Drug Profile
103 dexamethasone acetate + melatonin - Drug Profile
107 EPO-Variant - Drug Profile
108 ESN-502 - Drug Profile
109 felbamate - Drug Profile
110 FIB-117 - Drug Profile
111 glyburide - Drug Profile
112 HBI-002 - Drug Profile
114 HBI-137 - Drug Profile
115 HBN-1 - Drug Profile
116 HBN-2 - Drug Profile
117 HPI-201 - Drug Profile
118 ibudilast - Drug Profile
120 ICCN-100 - Drug Profile
122 IRX-4204 - Drug Profile
123 ISC-hpNSC - Drug Profile
125 JM-4 - Drug Profile
127 KPT-350 - Drug Profile
128 LB-201 - Drug Profile
129 LB-205 - Drug Profile
130 LM11A-31 - Drug Profile
131 Lpathomab - Drug Profile
132 MAP-4343 - Drug Profile
134 MultiStem - Drug Profile
135 ND-478 - Drug Profile
139 NNI-370 - Drug Profile
140 NNZ-2591 - Drug Profile
141 NSI-189 - Drug Profile
142 NSI-566 - Drug Profile
144 NVP-019 - Drug Profile
146 NVX-428 - Drug Profile
147 NX-210 - Drug Profile
148 PGI-02776 - Drug Profile
149 Posiphen - Drug Profile
151 progesterone - Drug Profile
153 PRV-002 - Drug Profile
154 PYC-35 - Drug Profile
155 PYC-36 - Drug Profile
156 PYC-38 - Drug Profile
157 PYC-98 - Drug Profile
158 R-503 - Drug Profile
159 RAP-701 - Drug Profile
161 RGN-352 - Drug Profile
162 SB-623 - Drug Profile
164 sepranolone - Drug Profile
166 Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
169 Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile
170 Small Molecule to Inhibit Amyloid Beta Peptide for Traumatic Brain Injury and Alzheimer s Disease - Drug Profile
171 Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile
172 Small Molecules to Activate P2Y Receptor for Stroke and Traumatic Brain Injury - Drug Profile
173 Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile
174 Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Drug Profile
175 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
176 Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile
177 Stem Cell Therapy for CNS Disorders - Drug Profile
178 STSE-15 - Drug Profile
179 T-094 - Drug Profile
180 TBI-121 - Drug Profile
181 TBI-122 - Drug Profile
182 TBI-123 - Drug Profile
183 trofinetide - Drug Profile
184 UH-0113 - Drug Profile
186 UH-0213 - Drug Profile
187 VG-1177 - Drug Profile
188 VitalHeme - Drug Profile
190 VOLT-02 - Drug Profile
192 Traumatic Brain Injury - Recent Pipeline Updates
193 Traumatic Brain Injury - Dormant Projects
250 Traumatic Brain Injury - Discontinued Products
253 Traumatic Brain Injury - Product Development Milestones
254 Featured News & Press Releases 2
260 Methodology 260 Coverage
260 Secondary Research
260 Primary Research
260 Expert Panel Validation
260 Contact Us
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.